New Mylan Launch Competes With Teva Generic

Earlier in March, Teva released a generic version of Pristiq extended release tablets for the US market. Mylan has now entered the market as well, in direct competition with Teva’s generic version of the drug. Pristiq is a serotonin and norepinephrine reuptake inhibitor that is used to treat major depressive disorder. According to IMS Health data, Pristiq had US sales of $853 million for the 12 months preceding January 2017.

Read the source article at The Pharma Letter